This is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767. This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.

Inclusion Criteria:

• Type 2 Diabetes Mellitus patients between the ages of 21 and 75 inclusive
• Patient is willing to discontinue current therapy for the duration of the study
• Patient is not a heavy drinker

Exclusion Criteria:

• Patient has a history of Type 1 diabetes and/or ketoacidosis
• Patient has severe diabetic retinopathy, or nephropathy, or neuropath
• Patient has has anti-hyperglycemic therapy including insulin, or rosiglitazone and pioglitazone or 2 or more oral agents in combination within 8 weeks prior to visit 1
• Patient has a history of, allergy to, intolerance or hypersensitive to troglitazone, rosiglitazone, or pioglitazone including history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments